Senescent Immunity in Elders and Vaccine Responses (SILVER)
NCT04077424
Completed
To study the effects of age on the immune system's response to flu vaccine and to study the connection between the immune system and physical and cognitive changes associated with aging.
Gender:
ALL
Ages:
Between 65 years and 125 years
Trial Updated:
06/16/2022
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Flu Vaccine
Register for Updates
Evaluating the Safety and Immunogenicity of an HIV-1 gp41 MPER-656 Liposome Vaccine in Healthy, HIV-uninfected Adult Participants
NCT03934541
Completed
The purpose of this study is to evaluate the safety and immunogenicity of an HIV-1 gp41 MPER-656 liposome vaccine in healthy, HIV-uninfected adults.
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
06/15/2022
Locations: Alabama CRS, Birmingham, Alabama +5 locations
Conditions: HIV Infections
Register for Updates
Safety and Immunogenicity of 20vPnC Coadministered With SIIV in Adults ≥65 Years of Age
NCT04526574
Completed
Study of the safety and immunogenicity of 20vPnC and influenza vaccine administered at the same visit or separately
Gender:
ALL
Ages:
65 years and above
Trial Updated:
06/15/2022
Locations: Alliance for Multispecialty Research, LLC, Mobile, Alabama +62 locations
Conditions: Pneumococcal Disease
Register for Updates
Ontogeny of Measles Immunity in Infants
NCT00240916
Completed
This is an immunogenicity study evaluating the development of the immune response of healthy infants following primary vaccination with Attenuvax at 6 or 9 months of age compared with responses in 12 month-old infants receiving MMR-II. Responses of infants receiving an early two dose measles vaccine regimen with the first dose given at 6 or 9 months followed by a second dose administered at 12 months will also be compared to infants given a single dose at 12 months of age (Table 2). The current... Read More
Gender:
ALL
Ages:
6 months and above
Trial Updated:
06/06/2022
Locations: Palo Alto Medical Foundation/Department of Pediatrics, Palo Alto, California +1 locations
Conditions: Measles
Register for Updates
Surveillance Study to Assess the Safety of Flublok Quadrivalent (Influenza Vaccine) in Pregnant Women and Their Offspring
NCT04460781
Completed
Primary Objective: To evaluate the safety of Flublok Quadrivalent influenza vaccine in pregnant women included in the VAP00003 Study (NCT03694392) and their offspring exposed during pregnancy or up to 28 days preceding the estimated date of conception with regards to pregnancy, birth, and neonatal/infant outcomes Secondary Objective:
Gender:
ALL
Ages:
64 years and below
Trial Updated:
05/23/2022
Locations: Kaiser Permanente Northern California, Oakland, California
Conditions: Influenza
Register for Updates
Study on a High-Dose Quadrivalent Influenza Vaccine Compared With Standard-Dose Quadrivalent Influenza Vaccine in Children 6 Months Through 35 Months of Age
NCT04544267
Suspended
The primary objective of the study is to compare the clinical efficacy of high-dose quadrivalent influenza vaccine (QIV-HD) to standard-dose quadrivalent influenza vaccine (QIV-SD) in participants 6 months through 35 months of age for the prevention of laboratory-confirmed influenza illness caused by any influenza A or B type. The secondary objectives of the study are: * To compare QIV-HD to QIV-SD: * in participants 6 months through 35 months of age for the prevention of laboratory-confirmed... Read More
Gender:
ALL
Ages:
Between 6 months and 35 months
Trial Updated:
05/03/2022
Locations: Investigational Site Number :8400008, San Diego, California +9 locations
Conditions: Influenza
Register for Updates
Evaluating the Safety and Immunogenicity of HIV Clade C DNA Vaccine and MF59- or AS01B-Adjuvanted Clade C Env Protein Vaccines in Various Combinations in Healthy, HIV-Uninfected Adults
NCT02915016
Completed
This study will evaluate the safety and immune response to the DNA-HIV-PT123 vaccine used in combination with one of two protein vaccines (Bivalent Subtype C gp120/MF59 or Bivalent Subtype C gp120/AS01B) in healthy, HIV-uninfected adults.
Gender:
ALL
Ages:
Between 18 years and 40 years
Trial Updated:
04/27/2022
Locations: Alabama CRS, Birmingham, Alabama +16 locations
Conditions: HIV Infections
Register for Updates
Dose-ranging Study of an Investigational Yellow Fever Candidate Vaccine in Adults
NCT04142086
Completed
The primary objectives of the study are: * To describe the safety profile of each of the 3 dosages of vYF and of YF-VAX® within the 28 days post-vaccination and up to the 6 months (Day 180) post-vaccination visit * To describe the antibody responses elicited by each of the 3 dosages of vYF and by YF-VAX on Day 0 pre-vaccination and then on Day 10, Day 14, Day 28 and 6 months (Day 180) post-vaccination overall and by baseline flavivirus serostatus * To quantify the detectable yellow fever (YF) v... Read More
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
04/22/2022
Locations: Investigational Site Number 8400001, Silver Spring, Maryland
Conditions: Yellow Fever (Healthy Volunteers)
Register for Updates
Rates of Pertussis Disease Among Persons Receiving Pentacel® or Other Pertussis Vaccines
NCT01129362
Completed
The purpose of this cohort study is to determine vaccine-specific rates of pertussis disease during the period of the study, among Wisconsin residents younger than 60 months of age (the Surveillance Population), and to descriptively compare the proportion of such persons vaccinated with Pentacel® vaccine who acquire pertussis disease to the proportion of such persons vaccinated with any other Diphtheria and Tetanus Toxoids and Acellular Pertussis (DTaP) vaccine who acquire pertussis disease. Pr... Read More
Gender:
ALL
Ages:
59 months and below
Trial Updated:
04/21/2022
Locations: Not set, Madison, Wisconsin +1 locations
Conditions: Pertussis
Register for Updates
Immune Response and Potential Booster for Patients Who Have Received HER2-pulsed DC1
NCT03630809
Terminated
The purpose of this study is to learn more about how to treat patients with a diagnosis of diagnosis of Human Epidermal Growth Factor Receptor 2/neu (HER-2/neu) positive breast cancer in the past, who were previously treated with HER-2/neu-directed dendritic cells (DC) vaccines. There is evidence that the use of anti-HER2 dendritic cell (DC) study vaccines could improve response to breast cancer therapy and be an important step in the prevention of recurrence. This study will use a Dendritic C... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/15/2022
Locations: H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
Conditions: Breast Cancer, HER2-positive Breast Cancer, HER-2 Gene Amplification, HER2 Positive Breast Carcinoma, HER-2 Protein Overexpression, Breast Cancer, Male, Breast Cancer Female
Register for Updates
Evaluating the Safety and Immunogenicity of Env (A,B,C,A/E)/Gag (C) DNA and gp120 (A,B,C,A/E) Protein/GLA-SE HIV Vaccines, Given Individually or Co-administered, in Healthy, HIV-1-Uninfected Adults
NCT03409276
Completed
The purpose of this study is to evaluate the safety, tolerability, and immunogenicity of env (A,B,C,A/E)/gag (C) DNA and gp120 (A,B,C,A/E) protein/GLA-SE HIV-1 vaccines (PDPHV-201401) as a prime-boost regimen or co-administered in repeated doses, in healthy, HIV-1-uninfected adults.
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
03/28/2022
Locations: Alabama CRS, Birmingham, Alabama +5 locations
Conditions: HIV Infections
Register for Updates
HIV-1-Gag Conserved-Element DNA Vaccine (p24CE) Vaccine Study
NCT03560258
Completed
This study evaluated the safety, immunogenicity, and preliminary assessment of efficacy of a novel vaccine encoding conserved elements (CE) of the HIV-1 Gag core protein, p24Gag, as a therapeutic vaccine in HIV-1 infected persons who were on antiretroviral therapy (ART). The study aimed to induce potent virus-specific cytotoxic T lymphocytes (CTL) responses.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
03/28/2022
Locations: Alabama CRS, Birmingham, Alabama +14 locations
Conditions: HIV Infections
Register for Updates